These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12814853)

  • 21. Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
    Judge R; Wagner BE
    J Clin Psychiatry; 1999 Nov; 60(11):795-6. PubMed ID: 10584775
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
    Feighner JP; Entsuah AR; McPherson MK
    J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder.
    Rickels K; Mangano R; Khan A
    J Clin Psychopharmacol; 2004 Oct; 24(5):488-96. PubMed ID: 15349004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.
    Lenox-Smith AJ; Reynolds A
    Br J Gen Pract; 2003 Oct; 53(495):772-7. PubMed ID: 14601352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release.
    Boyer P; Mahé V; Hackett D
    Eur Psychiatry; 2004 Aug; 19(5):272-9. PubMed ID: 15276659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of symptom-free days in generalized anxiety disorder.
    Wan GJ; Zhang HF; Tedeschi MA; Hackett D
    Curr Med Res Opin; 2006 Mar; 22(3):587-91. PubMed ID: 16574041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety of SSRIs in generalised anxiety disorder: any reason to be anxious?
    Masand PS; Gupta S
    Expert Opin Drug Saf; 2003 Sep; 2(5):485-93. PubMed ID: 12946249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
    Liebowitz MR; Gelenberg AJ; Munjack D
    Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
    Khan A; Upton GV; Rudolph RL; Entsuah R; Leventer SM
    J Clin Psychopharmacol; 1998 Feb; 18(1):19-25. PubMed ID: 9472838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mergers and acquisitions among psychotropics: antidepressant takeover of anxiety may now be complete.
    Stahl SM
    J Clin Psychiatry; 1999 May; 60(5):282-3. PubMed ID: 10362433
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generalized anxiety disorder in family practice patients.
    Magill MK; Gunning K
    Am Fam Physician; 2000 Oct; 62(7):1497, 1501-2, 1504. PubMed ID: 11037071
    [No Abstract]   [Full Text] [Related]  

  • 33. Venlafaxine: a 2003 update.
    Gutierrez MA; Stimmel GL; Aiso JY
    Clin Ther; 2003 Aug; 25(8):2138-54. PubMed ID: 14512125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom.
    Guest JF; Russ J; Lenox-Smith A
    Eur J Health Econ; 2005 Jun; 6(2):136-45. PubMed ID: 15682285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR; DuPont RL; Hedges D; Haskins JT
    J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
    Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
    J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
    Sir A; D'Souza RF; Uguz S; George T; Vahip S; Hopwood M; Martin AJ; Lam W; Burt T
    J Clin Psychiatry; 2005 Oct; 66(10):1312-20. PubMed ID: 16259546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do venlafaxine XR and paroxetine equally influence negative and positive affect?
    Dichter GS; Tomarken AJ; Freid CM; Addington S; Shelton RC
    J Affect Disord; 2005 Apr; 85(3):333-9. PubMed ID: 15780704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escitalopram versus venlafaxine XR in the treatment of depression.
    Montgomery SA; Andersen HF
    Int Clin Psychopharmacol; 2006 Sep; 21(5):297-309. PubMed ID: 16877901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.